Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized open-label study of ensartinib (X-396) versus crizotinib in ALK-positive non-small cell lung cancer
MOH_2017-04-04_000301Phase 3Recruiting
- Sponsor
- Xcovery
- Start
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing Ensartinib with Crizotinib (2 arms). Primary endpoint: Progression-free survival. Started Dec 2016; status: recruiting.
02
Drugs
ensartinibcrizotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on MOH_2017-04-04_000301.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-04-04_000301.